home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
TIME: Almanac 1990
/
1990 Time Magazine Compact Almanac, The (1991)(Time).iso
/
time
/
032089
/
03208900.006
< prev
next >
Wrap
Text File
|
1990-09-17
|
3KB
|
52 lines
MEDICINE, Page 61When Less May Be MoreA heart study finds drugs as effective as invasive methods
When people have a heart attack today, they are likely to be
given powerful drugs to dissolve the clots that block the flow of
blood to the cardiac muscle. But the drugs are generally used only
to buy time until invasive procedures can be performed. These
include angiography, the injection of a material into the coronary
arteries to identify by X ray the 1 patient in 6 apt to have
another attack; and balloon angioplasty, the threading into a
blocked artery of a catheter with a tiny balloon on the end that
presses plaque against the artery wall and widens the channel.
Now a new and controversial study has emerged to challenge this
conventional treatment. Published last week in the New England
Journal of Medicine, it concludes that immediate angiography and
angioplasty, both costly and somewhat risky techniques, are
unnecessary in most heart-attack cases. The 50-hospital study,
sponsored by the National Institutes of Health and known as TIMI
II (for thrombolysis in myocardial infarction phase II trial),
involved 3,262 patients who had suffered apparent heart attacks.
Within four hours of their attacks, all patients received a
powerful clot dissolver, known as TPA (tissue plasminogen
activator), along with heparin and aspirin to inhibit blood
coagulation. Of the 1,636 patients in the invasive-strategy group,
928 underwent angiography and angioplasty within 18 to 48 hours
after their attacks.
The results were surprising: after six weeks, the number of
deaths and repeat heart attacks were similar for each group, a
strong indication that there was no advantage in having
angioplasty. The study's conclusions: angiography and angioplasty
can be safely put off until patients show recurrent signs of a
deficient blood supply to the heart muscle.
Not all cardiologists agreed with TIMI II's conclusions. Dr.
Geoffrey Hartzler of the Mid America Heart Institute in Kansas City
took issue because the study excluded patients age 76 and over, as
well as anyone with a history of bypass surgery, heart-valve
replacement, cerebrovascular disease, or other serious illness.
"These were low-risk people, and it's a bad rap for angioplasty,"
he complained. "In fact, direct angioplasty alone, with no
clot-dissolving drugs, is probably the single most effective
treatment for acute heart attack."
Nonetheless, the trial has enormous implications for the
routine care of heart-attack patients. Community hospitals with
well-equipped coronary-care units, for example, could offer the
relatively simple drug treatment and send patients in real need of
angioplasty or bypass to specialized centers. If cardiologists
adopt TIMI II's conservative strategy, the estimated financial
savings could total $200 million a year.